首页> 外文期刊>Egyptian Journal of Medical Human Genetics >XmnI polymorphism: Relation to β-thalassemia phenotype and genotype in Egyptian Children
【24h】

XmnI polymorphism: Relation to β-thalassemia phenotype and genotype in Egyptian Children

机译:XmnI多态性:与埃及儿童β地中海贫血表型和基因型的关系

获取原文
           

摘要

Background β-Globin mutations with Xmn1 site might be associated with elevated HbF expression which may in turn ameliorate the severity of β-thalassemia phenotype. Aim of the study To investigate the frequency of ?158 (C>T) XmnI polymorphism among Egyptian Children and young adults with β-thalassemia, to examine the relationship between XmnI polymorphism and β-thalassemia genotypes and phenotypes and to assess the possible relation of XmnI polymorphism and response to hydroxyurea (Hu) therapy. Patients and methods Seventy-two β-thalassemia patients (37 females; M/F ratio 0.95) with a mean age of 7.53±6.99 were included. Laboratory investigations included Complete blood count (CBC), Hb electrophoresis by high performance liquid chromatography (HPLC), β-thalassemia mutation identification by the reverse dot blot hybridization technique (RDB) and detection of XmnlGg polymorphism by RFLP. Results The frequency of positive heterozygote XmnI gene polymorphism was 8.3%. Eighty-three percent of XmnIGγ +/? patients were never transfused ( p =0.001) and had higher total hemoglobin compared to XmnIGγ ?/? ( p =0.01); while mean HbF was higher among XmnIGγ +/? patients compared to the other group but the difference was marginally insignificant ( p =0.06). β-Thalassemia mutation IVS II-1 showed relatively higher XmnI polymorphism frequency (50%) and followed by its frequency among 10 undefined β-thalassemia mutations which was 20%. The frequency of positive heterozygote XmnI gene polymorphism was 11.6% among the TI group vs. 3.5% among the TM group ( p =0.4). Among 20 cases who received HU; 5/14 responders vs. 1/6 none responder had positive heterozygote XmnI gene polymorphism ( p =1.0). Conclusions and recommendations In conclusion, molecular determination of genetic markers in childhood will help to identify phenotypes of our patients and to avoid over or under treatment strategies. Further prospective studies concerning the genetic markers that could predict the response to hemoglobin F inducers like hydroxyurea are highly recommended.
机译:具有Xmn1位点的背景β球蛋白突变可能与HbF表达升高有关,这可能反过来会改善β地中海贫血表型的严重性。研究的目的是调查埃及地中海贫血儿童和年轻人中?158(C> T)XmnI基因多态性的频率,研究XmnI基因多态性与β地中海贫血基因型和表型之间的关系,并评估可能的相关性。 XmnI多态性和对羟基脲(Hu)治疗的反应。患者和方法纳入平均年龄为7.53±6.99的72例β地中海贫血患者(37例女性; M / F比为0.95)。实验室研究包括全血细胞计数(CBC),通过高效液相色谱(HPLC)进行的Hb电泳,通过反向斑点杂交技术(RDB)鉴定的β地中海贫血突变以及通过RFLP检测XmnlGg多态性。结果杂合子XmnI基因多态性阳性率为8.3%。 XmnIGγ+ /?的百分之八十三与XmnIGγ?/?相比,患者从未输血(p = 0.001)并且总血红蛋白更高。 (p = 0.01);而XmnIGγ+ /?之间的平均HbF较高。与另一组患者相比,差异很小(p = 0.06)。 β-地中海贫血突变IVS II-1表现出相对较高的XmnI多态性频率(50%),其次是10个未定义的β-地中海贫血突变的频率(20%)。 TI组阳性杂合子XmnI基因多态性阳性率高于TM组3.5%(p = 0.4)。在20例接受HU的病例中; 5/14应答者与1/6应答者相比,无应答者具有阳性的杂合子XmnI基因多态性(p = 1.0)。结论和建议总之,儿童期遗传标记的分子测定将有助于鉴定我们患者的表型,并避免治疗策略过度或不足。强烈建议进行有关可预测对血红蛋白F诱导剂(如羟基脲)反应的遗传标记的前瞻性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号